INTERFERONS IN ONCOLOGY
暂无分享,去创建一个
[1] S. Seki,et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis , 1995, The Lancet.
[2] S. Fosså,et al. Interferon-alpha and survival in renal cell cancer. , 1995, British journal of urology.
[3] S. Richards,et al. UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response , 1995, The Lancet.
[4] W. Scheithauer,et al. Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-alpha: an overview of clinical trials. , 1995, European journal of cancer.
[5] M. Kriegmair,et al. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. , 1995, Urology.
[6] H. Senn,et al. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] M. Grever,et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A. Cortelezzi,et al. Interferon alfa‐2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study , 1995, British journal of haematology.
[9] C. Falkson. Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma , 1995, Medical oncology.
[10] F. de Marinis,et al. Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force. , 1995, British Journal of Cancer.
[11] S. Rosenberg,et al. Immunotherapy and gene therapy of cancer. , 1991, Advances in surgery.
[12] J. Jett,et al. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] P. Queirolo,et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Eggermont,et al. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. , 1994, Melanoma research.
[15] G. Flandrin,et al. Hairy cell leukemia. An update on a cohort of 93 patients treated in a single institution. Effects of interferon in patients relapsing after splenectomy and in patients with or without maintenance treatment. , 1994, Leukemia & lymphoma.
[16] B. Coiffier,et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. , 1993, The New England journal of medicine.
[17] G. Scagliotti,et al. Combination of chemotherapy and recombinant alpha‐interferon in advanced non‐small cell lung cancer: Multicentric randomized FONICAP trial report , 1993, Cancer.
[18] P. Hersey,et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. , 1993, Melanoma research.
[19] G. Gahrton,et al. Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden , 1993 .
[20] W. Velasquez,et al. CHOP-Bleo plus interferon for stage IV low-grade lymphoma. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] S. McDonald,et al. Combined Betaseron R (recombinant human interferon beta) and radiation for inoperable non-small cell lung cancer. , 1993, International journal of radiation oncology, biology, physics.
[22] R. Dorr. Interferon-alpha in malignant and viral diseases. A review. , 1993, Drugs.
[23] M. Oken,et al. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. , 1992, The New England journal of medicine.
[24] D. Grandér,et al. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] K. Cantell,et al. Natural interferon alfa as maintenance therapy for small cell lung cancer. , 1992, European journal of cancer.
[26] P. Volberding,et al. Interferon-α2a in the Treatment of Acquired Immunodeficiency Syndrome-Related Kaposi's Sarcoma , 1991 .
[27] K. Öberg. The Role of Interferons in Neuroendocrine Tumours and Aspects of Mechanisms of Action , 1991 .
[28] M. Ratain,et al. Survival Experience of 195 Patients with Hairy Cell Leukemia Treated in a Multi-Institutional Study with Interferon-Alfa 2B. , 1991, Leukemia & lymphoma.
[29] S. Wadler,et al. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] R. Gale,et al. Chronic myeloid leukemia. , 1992, The American journal of medicine.
[31] J. Lindenmann,et al. Virus interference. I. The interferon , 1957, Proceedings of the Royal Society of London. Series B - Biological Sciences.